echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > FDA approves listing of interferon gamma (IFN) antibody Gamifant (emapalumab-lzsg)

    FDA approves listing of interferon gamma (IFN) antibody Gamifant (emapalumab-lzsg)

    • Last Update: 2020-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    today, Sobi and Novimmune SA(http://jointly announced that the U.SFDA(http://approved the joint development of the interferon (IFN)antibody Gamifant (emapalumab-lzg) for the treatment of children or adult primary phage lymphocytic lymphocytic associtoma (HLH) patientsAbout Gamifant
    Gamifant is a monoclonal antibody for IFNIt can be combined with IFN and its effectsGamifant has been granted FDA-awarded ground-breaking therapeutic stakes and orphan drug eligibility, andnew drug(http://applications have also been eligible for priority reviewGamifant was approved to be co-administered with the steroid therapy dexamethasone, administered twice a week through intravenous drips until the patient received HSCTrelated research
    this approval is based on Gamifant's performance in a global, multicenter, open label, single arm critical 2/3 clinicaltrial (http:// in this trial, 27 patients with primary HLH received a combination of Gamifant and Dexamethasone These patients did not respond to conventional therapies, were poorly responsive, or intolerant results showed that Gamifant reached the main end of the trial, with a total remission rate of 63% after six months of treatment Moreover, 70% of patients continued to receive HSCT
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.